XLON
LABS
Market cap202mUSD
Apr 17, Last price
43.10GBP
Name
Life Science REIT PLC
Chart & Performance
P/E
—
P/S
7.43
EPS
—
Div Yield, %
4.64%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
20m
+1.84%
Net income
-14m
L-35.61%
CFO
13m
+69.68%
Dividend
Oct 03, 20241 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Life Science REIT Plc functions as an investment enterprise, with the intention of operating as a Real Estate Investment Trust (REIT). This company, which commenced operations on July 27, 2021, from its headquarters in London, United Kingdom, aims to offer its shareholders a compelling aggregate return.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | ||||
Unusual Expense (Income) | ||||
NOPBT | ||||
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | ||||
Net income | ||||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | ||||
BB yield | ||||
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | ||||
| Cash flow | ||||
Cash from operating activities | ||||
CAPEX | ||||
Cash from investing activities | ||||
Cash from financing activities | ||||
FCF | ||||
| Balance | ||||
Cash | ||||
Long term investments | ||||
Excess cash | ||||
Stockholders' equity | ||||
Invested Capital | ||||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | ||||
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | ||||
EV/EBITDA | ||||
Interest | ||||
Interest/NOPBT | ||||